RNAC Stock Summary and Trading Ideas (Cartesian Therapeutics | NASDAQ:RNAC)

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Cartesian Therapeutics trades on the NASDAQ stock market under the symbol RNAC.

As of December 23, 2025, RNAC stock price declined to $6.52 with 90,645 million shares trading.

RNAC has a beta of 2.55, meaning it tends to be more sensitive to market movements. RNAC has a correlation of 0.33 to the broad based SPY ETF.

RNAC has a market cap of $169.53 million. This is considered a Micro Cap stock.

Last quarter Cartesian Therapeutics reported $452,000 in Revenue and -$1.38 earnings per share. This beat revenue expectation by $225,464 and missed earnings estimates by -$.68.

The top ETF exchange traded funds that RNAC belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

RNAC has underperformed the market in the last year with a price return of -65.7% while the SPY ETF gained +17.4%. RNAC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.1% and -3.0%, respectively, while the SPY returned +3.3% and +0.8%, respectively.

RNAC support price is $6.28 and resistance is $7.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAC shares will trade within this expected range on the day.